Jansen J, Zwaan F E, Haak H L, te Velde J, Guiot H F, Sabbe L J, Eernisse J G, Tricot G J, van Rood J J
Scand J Haematol. 1982 Apr;28(4):341-51. doi: 10.1111/j.1600-0609.1982.tb00536.x.
20 patients with severe aplastic anemia were treated with anti-thymocyte globulin (ATG), 6 of them in combination with haplo-identical bone marrow. 7 patients (35%) showed a good clinical response within 6 months; they were off transfusions and had greater than or equal to 0.8 x 10(9)/l neutrophils. ATG had the greatest effect on red-cell production and the least on platelet production. The hematological recovery with ATG could not be predicted from the bone-marrow histology, CFU-c growth, or clinical data. However, patients with strong HLA antibodies seemed to respond more often. The actuarial survival was 55% at 5 years. Under intensive supportive care, even 7 out of 12 non-responders were alive after 1 year. ATG appears to be a useful form of therapy for patients with severe aplastic anemia who are not candidates for bone-marrow transplantation.
20例重型再生障碍性贫血患者接受了抗胸腺细胞球蛋白（ATG）治疗，其中6例联合单倍体相合骨髓治疗。7例患者（35%）在6个月内出现良好的临床反应；他们不再需要输血，中性粒细胞计数大于或等于0.8×10⁹/L。ATG对红细胞生成的影响最大，对血小板生成的影响最小。无法根据骨髓组织学、CFU-c生长情况或临床数据预测ATG治疗后的血液学恢复情况。然而，具有强HLA抗体的患者似乎更常出现反应。5年时的精算生存率为55%。在强化支持治疗下，12例无反应者中甚至有7例在1年后仍存活。对于不适合进行骨髓移植的重型再生障碍性贫血患者，ATG似乎是一种有效的治疗方式。
